New insider activity at Outset Medical ( (OM) ) has taken place on January 21, 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Outset Medical’s Chair and CEO, Leslie Trigg, recently sold 13,914 shares of the company’s stock in a transaction valued at $71,091, signaling a notable insider move that investors may watch closely.
Recent Updates on OM stock
Over the last 24 hours, Outset Medical shares have traded against a backdrop of mixed fundamentals and recalibrated analyst expectations. The company issued preliminary 2025 results showing modest revenue growth of about 5% year over year, improved cash efficiency with a sharp reduction in operating cash burn, and expanding operational traction as more than 1,000 sites now use its Tablo dialysis system for roughly 1 million treatments annually. Despite these operational positives, sentiment and valuation remain pressured by ongoing losses, weak cash flow metrics, and bearish technical signals, which continue to weigh on the stock’s overall profile. Analyst price target reductions cited in the articles are driven less by company‑specific downgrades to its long‑term dialysis opportunity and more by broader MedTech sector repositioning following 2025 pressures, as firms rebalanced their coverage toward larger, more established names while still recognizing Outset’s growth potential. Governance news also featured, with the appointment of experienced medtech executive Karen Prange to the board and Compensation Committee, viewed as strengthening commercial and acute‑care expertise as the company heads into 2026 with a strong backlog and pipeline.
Spark’s Take on OM Stock
According to Spark, TipRanks’ AI Analyst, OM is a Neutral.
The score is held back primarily by continued losses and only moderate cash-flow progress, despite strong trailing revenue growth and sharply improved leverage. Technicals remain mixed with a pressured longer-term trend, and valuation offers limited support given the negative P/E and no dividend. Recent updates (earnings call and preliminary results) show improving margins/cash use, but guidance was lowered and execution risk persists due to sales leadership disruption and deal timing variability.
To see Spark’s full report on OM stock, click here.
More about Outset Medical
YTD Price Performance: 36.12%
Average Trading Volume: 991,299
Technical Sentiment Signal: Strong Sell
Current Market Cap: $96.1M